Latest news

Thumbnail image for Teva’s anti-CGRP drug under review for migraine

Teva’s anti-CGRP drug under review for migraine

US regulators are now reviewing Teva Pharmaceutical’s experimental anti-CGRP therapy fremanezumab for the preventive treatment of migraine, and have also granted the drug a fast track designation for the prevention of cluster headache.

19th December 2017

Thumbnail image for US priority review for AZ’ Tagrisso

US priority review for AZ’ Tagrisso

US regulators are undertaking a speedy review of AstraZeneca's application to market Tagrisso as first-line treatment for lung cancer.

18th December 2017

Thumbnail image for Horizon expands agreement with Roche Diagnostics

Horizon expands agreement with Roche Diagnostics

Cambridge, UK-based Horizon Discovery has expanded its relationship with Roche Diagnostics with a new agreement to assist in the development of immunohistochemistry (IHC) assays.

18th December 2017

Thumbnail image for Pfizer’s Xeljanz wins US nod for psoriatic arthritis

Pfizer’s Xeljanz wins US nod for psoriatic arthritis

Pfizer Xeljanz and Xeljanz XR have received US marketing clearance for the treatment of adults with active psoriatic arthritis who have failed to respond or are intolerant to methotrexate or other disease-modifying antirheumatic drugs.

18th December 2017

Thumbnail image for Seven therapies backed for EU approval

Seven therapies backed for EU approval

Seven therapies have been put forward for approval in the European Union, bringing closer new options for a range of conditions including Crohn’s disease, diabetes and cancer.

18th December 2017

Thumbnail image for Shire and partners launch Irish haemophilia study

Shire and partners launch Irish haemophilia study

Shire, the Royal College of Surgeons Ireland (RCSI) and Science Foundation Ireland (SFI), in collaboration with the Irish Haemophilia Society, have initiated a new study that aims to better personalise the care of haemophilia patients.

15th December 2017

Thumbnail image for Cancer Research Technology links with Celgene

Cancer Research Technology links with Celgene

Cancer Research UK’s subsidiary Cancer Research Technology (CRT) has signed a five-year drug-discovery deal with Celgene to develop and commercialise new anti-cancer treatments.

15th December 2017

Previous  --   2 3 4 5 6 7 8 9 10 11   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download